Advanced Magnetics' Combidex "Approvable" Letter Requests More Efficacy Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The decision follows the Oncologic Drugs Advisory Committee vote that current data do not support approval of the imaging agent for the proposed indication. FDA suggested that the data be "limited to a well-defined population of specific cancer types," the company says.
You may also be interested in...
EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition
Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.
EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition
Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.
Advanced Magnetics To Weigh European Trial Data For Combidex “Approvable” Response
European development partner Guerbet has submitted a marketing application to the EMEA seeking a narrower indication for the molecular imaging agent.